Wire · operational-macro
Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLC
◆ Sectors
Drug Discovery
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
Elticertinib has been granted FDA Fast Track designation for treating NSCLC with EGFR exon 20 mutations, potentially expediting its development and review.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
You need to prepare for quicker market entry and tighter regulatory timelines as FDA Fast Track status opens earlier access for your EGFR exon 20 NSCLC therapies.
◆ Coverage
1 source · 18 Nov 2026
◆ Related on Wire
◆ Topics
Drug Discoveryfdafast-tracknsclcegfr-mutationoncology